News
The Oncology Evaluation Center: Implementation of a same-day evaluation and treatment center to avoid unnecessary ED visits. - ASCO Home / Posters / Disclaimer ...
Incidence, characteristics, and survival of patients with <I>EGFR</I>-mutant lung cancers with <I>EGFR T790M</I> at diagnosis identified in the lung cancer mutation consortium (LCMC). - ASCO Home / ...
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with <em>BRAF</em> V600E-mutant (<em>BRAF</em><sup>V600E</sup>) metastatic non-small ...
Initial experience with an innovative pilot program evaluating a multidisciplinary approach to supportive care planning in a survivorship clinic setting. - ASCO Home / Posters / Disclaimer ...
Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). - ASCO ...
Cetuximab every second week in combination with daily encorafenib in patients with BRAF V600E mutated metastatic colorectal cancer: Interim analysis from NEW BEACON. - ASCO Home / Posters / Disclaimer ...
Sign in to explore collection of abstracts, journal articles, posters, videos, and slides.
© 2025 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma. - ASCO Home / ...
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and survival in recurrent ovarian cancer patients: An individual participant data meta-analysis of the ...
Sign in to explore collection of abstracts, journal articles, posters, videos, and slides.
Sign in to explore collection of abstracts, journal articles, posters, videos, and slides.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback